247133-32-0 Usage
Uses
Used in Pharmaceutical Industry:
1,4-Piperidinedicarboxylic acid, 4-(2-hydroxyethyl)-, 1-(1,1-dimethylethyl) 4-ethyl ester is used as an intermediate in the synthesis of various pharmaceutical compounds for its ability to be modified and incorporated into different drug molecules.
Used in Chemical Synthesis:
In the chemical industry, 1,4-Piperidinedicarboxylic acid, 4-(2-hydroxyethyl)-, 1-(1,1-dimethylethyl) 4-ethyl ester is used as a building block for the creation of more complex molecules, taking advantage of its reactive functional groups and structural features.
Used in Research and Development:
This piperidine derivative is also utilized in research and development settings, where it can be studied for its potential applications in various fields, such as material science, drug discovery, and chemical engineering.
Check Digit Verification of cas no
The CAS Registry Mumber 247133-32-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,4,7,1,3 and 3 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 247133-32:
(8*2)+(7*4)+(6*7)+(5*1)+(4*3)+(3*3)+(2*3)+(1*2)=120
120 % 10 = 0
So 247133-32-0 is a valid CAS Registry Number.
InChI:InChI=1/C15H27NO5/c1-5-20-12(18)15(8-11-17)6-9-16(10-7-15)13(19)21-14(2,3)4/h17H,5-11H2,1-4H3
247133-32-0Relevant academic research and scientific papers
Amidine compounds
-
, (2008/06/13)
A compound of the formula [I] wherein R1, R2and R3are the same or different and each is hydrogen atom, wherein each symbol is as defined in the specification, a salt thereof or a prodrug thereof. The compound of the presen
4,4-Disubstituted cyclohexylamine NK1 receptor antagonists II
Cooper, Laura C.,Carlson, Emma J.,Castro, Jose L.,Chicchi, Gary G.,Dinnell, Kevin,Di Salvo, Jerry,Elliott, Jason M.,Hollingworth, Gregory J.,Kurtz, Marc M.,Ridgill, Mark P.,Rycroft, Wayne,Tsao, Kwei-Lan,Swain, Christopher J.
, p. 1759 - 1762 (2007/10/03)
A series of novel 4,4-disubstituted cyclohexylamines as NK1 receptor antagonists is described: modifications to the amine moiety retain NK1 receptor binding affinity whilst disrupting IKr affinity.
